{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:29:48Z","timestamp":1794479388917,"version":"4.9.1"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012513","name":"CIBER","doi-asserted-by":"publisher","award":["PID2023-148270OB-I00"],"award-info":[{"award-number":["PID2023-148270OB-I00"]}],"id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006049","name":"Comisi\u00f3n Sectorial de Investigaci\u00f3n Cient\u00edfica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.biopha.2026.119401","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:36:27Z","timestamp":1778621787000},"page":"119401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Expanding the therapeutic horizon in inflammatory bowel disease: The rise of non-cytokine compounds"],"prefix":"10.1016","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0327-9153","authenticated-orcid":false,"given":"\u00c1ngel","family":"De Prado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Javier","family":"Garc\u00eda-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Arribas-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier P.","family":"Gisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119401_bib1","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2147\/JIR.S353038","article-title":"Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics","volume":"15","author":"Lu","year":"2022","journal-title":"J. Inflamm. Res."},{"issue":"10114","key":"10.1016\/j.biopha.2026.119401_bib2","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2026.119401_bib3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","article-title":"The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission","volume":"8","author":"Burisch","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119401_bib4","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.autrev.2017.02.013","article-title":"IBD immunopathogenesis: a comprehensive review of inflammatory molecules","volume":"16","author":"Park","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","article-title":"Immunopathogenesis of IBD: current state of the art","volume":"13","author":"de Souza","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.autrev.2013.06.004","article-title":"Innate and adaptive immunity in inflammatory bowel disease","volume":"13","author":"Geremia","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biopha.2026.119401_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7247238","article-title":"A comprehensive review and update on the pathogenesis of inflammatory bowel disease","volume":"2019","author":"Guan","year":"2019","journal-title":"J. Immunol. Res"},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2026.119401_bib9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3389\/fphar.2019.00671","article-title":"Novel pharmacological therapy in inflammatory bowel diseases: beyond anti-tumor necrosis factor","volume":"10","author":"Pagnini","year":"2019","journal-title":"Front Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2026.119401_bib10","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","article-title":"Predictors of primary response to biologic treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice","volume":"14","author":"Gisbert","year":"2020","journal-title":"J. Crohns Colitis"},{"issue":"10","key":"10.1016\/j.biopha.2026.119401_bib11","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/jcm10102132","article-title":"Frequency and effectiveness of empirical anti-TNF dose intensification in inflammatory bowel disease: systematic review with meta-analysis","volume":"10","author":"Guberna","year":"2021","journal-title":"J. Clin. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119401_bib12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/17474124.2022.2155136","article-title":"R G. An update on efficacy and safety comparison of biologics in treatment of inflammatory bowel disease targeting TNF-\u03b1, interleukins, leukocyte trafficking, Janus-kinase, and sphingosine-1-phosphate receptor","volume":"17","author":"Sarangi","year":"2023","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119401_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.744804","article-title":"Approaches to establishing tolerance in immune mediated diseases","volume":"12","author":"Huffaker","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41577-024-01077-7","article-title":"The renaissance of oral tolerance: merging tradition and new insights","volume":"25","author":"Cerovic","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2026.119401_bib15","doi-asserted-by":"crossref","first-page":"9987","DOI":"10.2147\/JIR.S492079","article-title":"Dissecting innate and adaptive immunity in inflammatory bowel disease: immune compartmentalization, microbiota crosstalk, and emerging therapies","volume":"17","author":"Yue","year":"2024","journal-title":"J. Inflamm. Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119401_bib16","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/ijms24021526","article-title":"Pathophysiology of inflammatory bowel disease: innate immune system","volume":"24","author":"Saez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2026.119401_bib17","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.3748\/wjg.v22.i7.2195","article-title":"Role of regulatory T cell in the pathogenesis of inflammatory bowel disease","volume":"22","author":"Yamada","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119401_bib18","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nri2156","article-title":"Getting to the site of inflammation: the leukocyte adhesion cascade updated","volume":"7","author":"Ley","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119401_bib19","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1053\/j.gastro.2014.08.044","article-title":"Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases","volume":"147","author":"Danese","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2026.119401_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1665530","article-title":"Fundamental and emerging insights into innate and adaptive immunity in inflammatory bowel diseases","volume":"16","author":"Monteleone","year":"2025","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119401_bib21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.gastro.2015.10.046","article-title":"Leukocyte trafficking to the small intestine and colon","volume":"150","author":"Habtezion","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2026.119401_bib22","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3389\/fimmu.2017.00891","article-title":"Anti-adhesion therapies in inflammatory bowel disease-molecular and clinical aspects","volume":"8","author":"Zundler","year":"2017","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.biopha.2026.119401_bib23","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3748\/wjg.v24.i17.1868","article-title":"Anti-integrin therapy for inflammatory bowel disease","volume":"24","author":"Park","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119401_bib24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biopha.2026.119401_bib25","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nrm2871","article-title":"The final steps of integrin activation: the end game","volume":"11","author":"Shattil","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119401_bib26","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1016\/j.cell.2024.04.049","article-title":"Ligand binding initiates single-molecule integrin conformational activation","volume":"187","author":"Li","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119401_bib27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pharmthera.2014.11.008","article-title":"Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease","volume":"147","author":"Mitroulis","year":"2015","journal-title":"Pharm. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41573-021-00284-4","article-title":"Emerging therapeutic opportunities for integrin inhibitors","volume":"21","author":"Slack","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.biopha.2026.119401_bib29","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.it.2023.06.007","article-title":"MAdCAM-1: a newly identified microbial 'gut check' for T cells","volume":"44","author":"Chelvanambi","year":"2023","journal-title":"Trends Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119401_bib30","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/ng.3760","article-title":"Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease","volume":"49","author":"de Lange","year":"2017","journal-title":"Nat. Genet."},{"issue":"18","key":"10.1016\/j.biopha.2026.119401_bib31","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119401_bib32","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.biopha.2026.119401_bib33","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J. Crohns Colitis"},{"issue":"5","key":"10.1016\/j.biopha.2026.119401_bib34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/ijms18050940","article-title":"Natalizumab in multiple sclerosis: long-term management","volume":"18","author":"Clerico","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2026.119401_bib35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119401_bib36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119401_bib37","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.biopha.2026.119401_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241258372","article-title":"Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis","volume":"17","author":"Gros","year":"2024","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.biopha.2026.119401_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231174953","article-title":"Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study","volume":"16","author":"Visuri","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119401_bib40","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: results from the US VICTORY Consortium","volume":"111","author":"Dulai","year":"2016","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119401_bib41","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(21)00298-3","article-title":"Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial","volume":"7","author":"Peyrin-Biroulet","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(21)00338-1","article-title":"Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials","volume":"7","author":"Rubin","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib43","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2468-1253(21)00295-8","article-title":"Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study","volume":"7","author":"Vermeire S","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2468-1253(22)00303-X","article-title":"Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial","volume":"8","author":"Sandborn","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119401_bib45","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.it.2011.06.003","article-title":"Intestinal CD103+ dendritic cells: master regulators of tolerance?","volume":"32","author":"Scott","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.biopha.2026.119401_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.912393","article-title":"An overview of tissue-resident memory T cells in the intestine: from physiological functions to pathological mechanisms","volume":"13","author":"Lyu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119401_bib47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1074-7613(00)80505-1","article-title":"Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet?","volume":"7","author":"O'Shea","year":"1997","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.biopha.2026.119401_bib49","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0092-8674(00)81288-X","article-title":"Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway","volume":"84","author":"Meraz","year":"1996","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.biopha.2026.119401_bib50","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119401_bib51","first-page":"1347","article-title":"JAK2, a third member of the JAK family of protein tyrosine kinases","volume":"7","author":"Harpur","year":"1992","journal-title":"Oncogene"},{"issue":"5187","key":"10.1016\/j.biopha.2026.119401_bib52","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1126\/science.7973658","article-title":"Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID","volume":"266","author":"Russell","year":"1994","journal-title":"Science"},{"issue":"5187","key":"10.1016\/j.biopha.2026.119401_bib53","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1126\/science.7973659","article-title":"Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits","volume":"266","author":"Miyazaki","year":"1994","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib54","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tem.2017.11.001","article-title":"JAK\/STAT - emerging players in metabolism","volume":"29","author":"Dodington","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2026.119401_bib55","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/S0092-8674(02)00701-8","article-title":"Cytokine signaling in 2002: new surprises in the Jak\/Stat pathway","volume":"109","author":"O'Shea","year":"2002","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.biopha.2026.119401_bib56","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0968-0004(94)90026-4","article-title":"Signaling by the cytokine receptor superfamily: JAKs and STATs","volume":"19","author":"Ihle","year":"1994","journal-title":"Trends Biochem. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib57","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"7","key":"10.1016\/j.biopha.2026.119401_bib58","doi-asserted-by":"crossref","first-page":"R424","DOI":"10.1016\/S0960-9822(06)00208-9","article-title":"Cytokines: shared receptors, distinct functions","volume":"7","author":"DiSanto","year":"1997","journal-title":"Curr. Biol."},{"key":"10.1016\/j.biopha.2026.119401_bib59","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.bi.64.070195.003201","article-title":"Transcriptional responses to polypeptide ligands: the JAK-STAT pathway","volume":"64","author":"Schindler","year":"1995","journal-title":"Annu Rev. Biochem."},{"issue":"7","key":"10.1016\/j.biopha.2026.119401_bib60","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1074\/jbc.270.7.3327","article-title":"Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha\/beta and for signal transduction","volume":"270","author":"Velazquez","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib61","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1084\/jem.181.1.399","article-title":"Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12","volume":"181","author":"Bacon","year":"1995","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.biopha.2026.119401_bib62","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5332","key":"10.1016\/j.biopha.2026.119401_bib63","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.277.5332.1630","article-title":"STATs and gene regulation","volume":"277","author":"Darnell","year":"1997","journal-title":"Science"},{"issue":"20","key":"10.1016\/j.biopha.2026.119401_bib64","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"42","key":"10.1016\/j.biopha.2026.119401_bib65","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1093\/eurheartj\/ehab447","article-title":"The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms","volume":"42","author":"Baldini","year":"2021","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.biopha.2026.119401_bib66","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tcb.2008.08.008","article-title":"Canonical and non-canonical JAK-STAT signaling","volume":"18","author":"Li","year":"2008","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.biopha.2026.119401_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107969","article-title":"Signal transducer and activator of transcription 3 signaling in tumor immune evasion","volume":"230","author":"Zhang","year":"2022","journal-title":"Pharm. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2026.119401_bib68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41568-022-00537-3","article-title":"STAT proteins in cancer: orchestration of metabolism","volume":"23","author":"Li","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119401_bib69","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the JAK\/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy","volume":"35","author":"Waldmann","year":"2017","journal-title":"Annu Rev. Immunol."},{"key":"10.1016\/j.biopha.2026.119401_bib70","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clim.2016.09.014","article-title":"Role of the JAK\/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases","volume":"189","author":"Yan","year":"2018","journal-title":"Clin. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119401_bib71","doi-asserted-by":"crossref","first-page":"a028449","DOI":"10.1101\/cshperspect.a028449","article-title":"The common cytokine receptor \u03b3 chain family of cytokines","volume":"10","author":"Lin","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119401_bib72","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.4049\/jimmunol.1303496","article-title":"Human lymphoid development in the absence of common \u03b3-chain receptor signaling","volume":"192","author":"Kohn","year":"2014","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119401_bib73","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.cell.2018.08.067","article-title":"Structural remodeling of the human colonic mesenchyme in inflammatory bowel disease","volume":"175","author":"Kinchen","year":"2018","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.biopha.2026.119401_bib74","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/ni.3278","article-title":"The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and regulates TH17 differentiation","volume":"16","author":"Lu","year":"2015","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119401_bib75","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ibd.21151","article-title":"Interleukin-19 protects mice from innate-mediated colonic inflammation","volume":"16","author":"Azuma","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"issue":"7","key":"10.1016\/j.biopha.2026.119401_bib76","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/ibd.20110","article-title":"Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis","volume":"13","author":"Wu","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119401_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","article-title":"Signaling through the JAK\/STAT pathway, recent advances and future challenges","volume":"285","author":"Kisseleva","year":"2002","journal-title":"Gene"},{"key":"10.1016\/j.biopha.2026.119401_bib78","article-title":"Janus kinase inhibitors for inflammatory bowel disease: concise questions and answers on their use in clinical practice","author":"Gisbert","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"issue":"4","key":"10.1016\/j.biopha.2026.119401_bib79","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/ecco-jcc\/jjad173","article-title":"Janus kinase inhibitors differentially inhibit specific cytokine signals in the mesenteric lymph node cells of inflammatory bowel disease patients","volume":"18","author":"Hindmarch","year":"2024","journal-title":"J. Crohns Colitis"},{"issue":"18","key":"10.1016\/j.biopha.2026.119401_bib80","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119401_bib81","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ecco-jcc\/jjx133","article-title":"Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies","volume":"12","author":"Pan\u00e9s","year":"2018","journal-title":"J. Crohns Colitis"},{"issue":"9","key":"10.1016\/j.biopha.2026.119401_bib82","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119401_bib83","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.biopha.2026.119401_bib84","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119401_bib85","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ibd\/izy364","article-title":"A JAK1 selective kinase inhibitor and tofacitinib affect macrophage activation and function","volume":"25","author":"De Vries","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"issue":"7","key":"10.1016\/j.biopha.2026.119401_bib86","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/ibd\/izad290","article-title":"Tofacitinib affects M1-like and M2-like polarization and tissue factor expression in macrophages of healthy donors and IBD patients","volume":"30","author":"Lethen","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.biopha.2026.119401_bib87","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jcmgh.2021.09.004","article-title":"Tofacitinib-induced modulation of intestinal adaptive and innate immunity and factors driving cellular and systemic pharmacokinetics","volume":"13","author":"Texler","year":"2022","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119401_bib88","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1136\/annrheumdis-2013-203756","article-title":"The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells","volume":"73","author":"Kubo","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2026.119401_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2025.100271","article-title":"Tofacitinib downregulates JAK1 and JAK3 on human intestinal monocytes and macrophages without affecting dendritic cells phenotype or function","volume":"10","author":"Arribas-Rodr\u00edguez","year":"2025","journal-title":"J. Transl. Autoimmun."},{"issue":"10341","key":"10.1016\/j.biopha.2026.119401_bib90","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.biopha.2026.119401_bib91","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib92","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/biomedicines13010190","article-title":"An analysis of the effectiveness and safety of upadacitinib in the treatment of inflammatory bowel disease: a multicenter real-world study","volume":"13","author":"Wu","year":"2025","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.biopha.2026.119401_bib93","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3390\/jcm14072232","article-title":"Real-world effectiveness and safety of upadacitinib in patients with ulcerative colitis: a systematic review and meta-analysis","volume":"14","author":"Taxonera","year":"2025","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib94","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: Mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin. Transl. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib95","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib96","first-page":"30","article-title":"Molecular modeling insights into upadacitinib selectivity upon binding to JAK protein family","volume":"15","author":"Taldaev","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"10.1016\/j.biopha.2026.119401_bib97","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheuma"},{"issue":"12","key":"10.1016\/j.biopha.2026.119401_bib98","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/ibd\/izab116","article-title":"Randomized controlled trial substudy of cell-specific mechanisms of janus kinase 1 inhibition with upadacitinib in the Crohn's disease intestinal mucosa: analysis from the CELEST study","volume":"27","author":"Aguilar","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"issue":"7","key":"10.1016\/j.biopha.2026.119401_bib99","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib is effective and safe in both ulcerative Colitis and Crohn's disease: prospective real-world experience","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119401_bib100","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/ibd\/izac246","article-title":"The clinical response of upadacitinib and risankizumab is associated with reduced inflammatory bowel disease anti-TNF-\u03b1 inadequate response mechanisms","volume":"29","author":"Wang","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"issue":"8","key":"10.1016\/j.biopha.2026.119401_bib101","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/17460441.2025.2522890","article-title":"The preclinical discovery and development of upadacitinib for the treatment of Crohn's disease","volume":"20","author":"Vieujean","year":"2025","journal-title":"Expert Opin. Drug Discov."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib102","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40262-022-01191-6","article-title":"Upadacitinib population pharmacokinetics and exposure-response relationships in ulcerative colitis patients","volume":"62","author":"Ponce-Bobadilla","year":"2023","journal-title":"Clin. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2026.119401_bib103","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/imt-2023-0116","article-title":"The role of filgotinib in ulcerative colitis and Crohn's disease","volume":"16","author":"Fanizza","year":"2024","journal-title":"Immunotherapy"},{"issue":"10066","key":"10.1016\/j.biopha.2026.119401_bib104","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.biopha.2026.119401_bib105","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/ibd\/izab253","article-title":"Effects of JAK1-preferential inhibitor filgotinib on circulating biomarkers and whole blood genes\/pathways of patients with moderately to severely active Crohn's disease","volume":"28","author":"Roblin","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"issue":"10292","key":"10.1016\/j.biopha.2026.119401_bib106","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2026.119401_bib107","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/ibd\/izae278","article-title":"Mediators of filgotinib treatment effects in ulcerative colitis: exploring circulating biomarkers in the phase 2b\/3 SELECTION study","volume":"31","author":"Nakase","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib108","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pharmthera.2007.04.006","article-title":"Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology","volume":"115","author":"Brinkmann","year":"2007","journal-title":"Pharm. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2026.119401_bib109","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nri2974","article-title":"The outs and the ins of sphingosine-1-phosphate in immunity","volume":"11","author":"Spiegel","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119401_bib110","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume":"16","author":"Peyrin-Biroulet","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.biopha.2026.119401_bib111","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s40265-024-02094-5","article-title":"Targeting the sphingosine-1-phosphate pathway: new opportunities in inflammatory bowel disease management","volume":"84","author":"Kitsou","year":"2024","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.biopha.2026.119401_bib112","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41575-021-00574-7","article-title":"Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease","volume":"19","author":"Verstockt","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib113","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2010.11.002","article-title":"Sphingosine-1-phosphate and immune regulation: trafficking and beyond","volume":"32","author":"Chi","year":"2011","journal-title":"Trends Pharm. Sci."},{"issue":"14","key":"10.1016\/j.biopha.2026.119401_bib114","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.biopha.2026.119401_bib115","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.cgh.2024.03.042","article-title":"Ozanimod in patients with moderate to severe ulcerative colitis naive to advanced therapies","volume":"22","author":"Sands","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119401_bib116","article-title":"Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: the yellowstone clinical trial program","volume":"122","author":"Feagan","year":"2022","journal-title":"Conte Clin. Trials"},{"issue":"10","key":"10.1016\/j.biopha.2026.119401_bib117","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/ecco-jcc\/jjae060","article-title":"Etrasimod for the treatment of ulcerative colitis: analysis of infection events from the ELEVATE UC clinical programme","volume":"18","author":"Regueiro","year":"2024","journal-title":"J. Crohns Colitis"},{"issue":"10383","key":"10.1016\/j.biopha.2026.119401_bib118","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.biopha.2026.119401_bib119","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J. Crohns Colitis"},{"issue":"5","key":"10.1016\/j.biopha.2026.119401_bib120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/imt-2022-0255","article-title":"Etrasimod for the treatment of ulcerative colitis","volume":"15","author":"Wils","year":"2023","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib121","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3748\/wjg.v29.i1.110","article-title":"Unveiling the biological role of sphingosine-1-phosphate receptor modulators in inflammatory bowel diseases","volume":"29","author":"Tourkochristou","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119401_bib122","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00535-024-02130-x","article-title":"Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment-insights from Phase II and III trials","volume":"59","author":"Massironi","year":"2024","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.biopha.2026.119401_bib123","article-title":"Long-term safety of vedolizumab in patients with ulcerative colitis\/Crohn's disease: a prospective observational study","author":"Louis","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119401_bib124","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/ecco-jcc\/jjad043","article-title":"Effectiveness and safety of vedolizumab in inflammatory bowel disease: a comprehensive meta-analysis of observational studies","volume":"17","author":"Macaluso","year":"2023","journal-title":"J. Crohns Colitis"},{"issue":"13","key":"10.1016\/j.biopha.2026.119401_bib125","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.3390\/jcm14134419","article-title":"Efficacy and safety of infliximab and vedolizumab maintenance therapy in patients with Crohn's disease and ulcerative colitis: a systematic review and meta-analysis","volume":"14","author":"Sands","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2026.119401_bib126","article-title":"Evaluating choice of biologics for isolated small-bowel Crohn's disease","author":"Tome","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"issue":"3","key":"10.1016\/j.biopha.2026.119401_bib127","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/apt.16436","article-title":"Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study","volume":"54","author":"Ko","year":"2021","journal-title":"Aliment Pharm. Ther."},{"issue":"13","key":"10.1016\/j.biopha.2026.119401_bib128","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.biopha.2026.119401_bib129","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.cgh.2021.07.038","article-title":"Comparative efficacy for infliximab vs vedolizumab in biologic naive ulcerative colitis","volume":"20","author":"Narula","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","article-title":"Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis","volume":"17","author":"Hanauer","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119401_bib131","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","article-title":"Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment","volume":"21","author":"Loftus","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119401_bib132","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119401_bib133","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119401_bib134","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2468-1253(25)00017-2","article-title":"Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study","volume":"10","author":"Panaccione","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119401_bib135","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40744-024-00658-1","article-title":"Long-term efficacy and safety following switch between upadacitinib and adalimumab in patients with rheumatoid arthritis: 5-year data from Select-Compare","volume":"11","author":"Fleischmann","year":"2024","journal-title":"Rheuma Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib136","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004857","article-title":"Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study","volume":"11","author":"Westhovens","year":"2025","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.biopha.2026.119401_bib137","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2026.119401_bib138","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.biopha.2026.119401_bib139","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1007\/s12325-025-03249-w","article-title":"Patient preferences for treatment attributes in inflammatory bowel disease: a discrete choice experiment among patients in five non-western countries","volume":"42","author":"Argollo","year":"2025","journal-title":"Adv. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2026.119401_bib140","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/ibd\/izae015","article-title":"Patient preferences for treatment attributes in inflammatory bowel disease: results from a large survey across seven European countries using a discrete choice experiment","volume":"30","author":"Fiorino","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.biopha.2026.119401_bib141","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/ecco-jcc\/jjac130","article-title":"Patients with inflammatory bowel disease have heterogeneous treatment preferences that are largely determined by the avoidance of abdominal pain and side effects [P-POWER IBD Study]","volume":"17","author":"Louis","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.biopha.2026.119401_bib142","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.trsl.2022.10.003","article-title":"Expression and function of \u03b14\u03b27 integrin predict the success of vedolizumab treatment in inflammatory bowel disease","volume":"253","author":"Schneider","year":"2023","journal-title":"Transl. Res"},{"issue":"7","key":"10.1016\/j.biopha.2026.119401_bib143","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/imcb.70039","article-title":"Serum proteomic and metabolomic analyses from patients with IBD identify biological pathways associated with treatment success with anti-integrin therapy","volume":"103","author":"Rioux","year":"2025","journal-title":"Immunol. Cell Biol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119401_bib144","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ecco-jcc\/jjad129","article-title":"Peripheral blood DNA methylation signatures and response to tofacitinib in moderate-to-severe ulcerative colitis","volume":"18","author":"Joustra","year":"2024","journal-title":"J. Crohns Colitis"},{"issue":"7","key":"10.1016\/j.biopha.2026.119401_bib145","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-083163","article-title":"Nordic inflammatory bowel disease treatment strategy trial: protocol for the NORDTREAT randomised controlled biomarker-strategy trial","volume":"14","author":"Rejler","year":"2024","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.biopha.2026.119401_bib146","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119401_bib147","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ueg2.12170","article-title":"Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study","volume":"9","author":"Goessens","year":"2021","journal-title":"U. Eur. Gastroenterol. J."},{"issue":"4","key":"10.1016\/j.biopha.2026.119401_bib148","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119401_bib149","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, Adalimumab, and Methotrexate combination therapy in Crohn's disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119401_bib150","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41577-024-01008-6","article-title":"Strategies for targeting cytokines in inflammatory bowel disease","volume":"24","author":"Neurath","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib151","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119401_bib152","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/gutjnl-2024-332919","article-title":"Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?","volume":"74","author":"Neurath","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2026.119401_bib153","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2013.06.007","article-title":"Involvement of JAK\/STAT signaling in the pathogenesis of inflammatory bowel disease","volume":"76","author":"Coskun","year":"2013","journal-title":"Pharm. Res."},{"issue":"11","key":"10.1016\/j.biopha.2026.119401_bib154","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/ecco-jcc\/jjad100","article-title":"Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis","volume":"17","author":"Solitano","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.biopha.2026.119401_bib155","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231159452","article-title":"Is there an optimal sequence of biologic therapies for inflammatory bowel disease?","volume":"16","author":"Bressler","year":"2023","journal-title":"Ther. Adv. Gastroenterol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226004361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226004361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:50:05Z","timestamp":1794477005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226004361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":155,"alternative-id":["S0753332226004361"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119401","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding the therapeutic horizon in inflammatory bowel disease: The rise of non-cytokine compounds","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119401"}}